| Literature DB >> 31936128 |
Maria Ferreira1, João Sousa1,2, Alberto Pais2, Carla Vitorino1,2,3.
Abstract
Technological development is in constant progress in the oncological field. The search for new concepts and strategies for improving cancer diagnosis, treatment and outcomes constitutes a necessary and continuous process, aiming at more specificity, efficiency, safety and better quality of life of the patients throughout the treatment. Nanotechnology embraces these purposes, offering a wide armamentarium of nanosized systems with the potential to incorporate both diagnosis and therapeutic features, towards real-time monitoring of cancer treatment. Within the nanotechnology field, magnetic nanosystems stand out as complex and promising nanoparticles with magnetic properties, that enable the use of these constructs for magnetic resonance imaging and thermal therapy purposes. Additionally, magnetic nanoparticles can be tailored for increased specificity and reduced toxicity, and functionalized with contrast, targeting and therapeutic agents, revealing great potential as multifunctional nanoplatforms for application in cancer theranostics. This review aims at providing a comprehensive description of the current designs, characterization techniques, synthesis methods, and the role of magnetic nanoparticles as promising nanotheranostic agents. A critical appraisal of the impact, potentialities and challenges associated with each technology is also presented.Entities:
Keywords: biomedical applications; cancer; diagnosis; drug delivery; magnetic nanoparticles; nanotheranostics; therapy
Year: 2020 PMID: 31936128 PMCID: PMC7014348 DOI: 10.3390/ma13020266
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.623
Figure 1Correlation between MNP (magnetic nanoparticle) size and magnetic domain. Key: Ds stands for superparamagnetism diameter threshold and Dc stands for critical diameter threshold.
Superparamagnetism (Ds) and critical (Dc) size thresholds for MNPs.
| Material | Ds (nm) | Dc (nm) |
|---|---|---|
| FePt | 4 | 55 |
| FeCo | 16 | 51 |
| Fe3O4 | 25 | 82 |
| γ-Fe2O3 | 30 | 90 |
| Co | 10 | 80 |
| CoPt | 3 | 57 |
| Co-Fe2O4 | 10 | 100 |
| Ni | 30 | 85 |
Benefits and limitations of the MNP synthesis methods.
| MNP Synthesis Methods | Advantages | Disadvantages | References |
|---|---|---|---|
| Mechanical attrition | Simple; inexpensive equipment; adequate for scale-up. | Contamination from the materials in the media and/or atmosphere; difficulty to consolidate the powder core without coarsening the crystalline structure. | [ |
| Thermal quenching | Up-scalable process; favorable composition control. | Elevated temperatures required; large size distribution; lack of homogeneity in microstructure. | [ |
| Pyrolysis | Reduced reaction times; high purity. | High-pressure and temperature conditions; gas as adsorbent and carrier; large size distribution; aggregation phenomena. | [ |
| Co-precipitation | Simple execution; adequate for the synthesis of complex metal oxide NPs; high reproducibility; inexpensive method. | Requires a nanoparticle separation step, for obtaining uniform size distribution; quasi-spherical NPs; risk of oxidation and aggregation phenomena. | [ |
| Thermal decomposition | Size control; narrow size distribution; crystallinity; Easy scale-up process. | Dilatory process; uses organic solvents; requires further steps to obtain water-soluble MNPs. | [ |
| Hydrothermal | Fine particles; no required organic solvents; no required post-treatment; Environmentally benign. | Long reaction times. | [ |
| Microemulsification | Simple method; adequate for in vitro and in vivo applications; controllable size and MNP morphology. | Low scalability; reduced quantity of MNPs synthesized; difficult removal of surfactant. | [ |
| Polyol-based | Uniform MNPs; size and shape control; simple and reproducible process. | May require high temperature and pressure environment for higher magnetization values. | [ |
| Sol-gel | Controlled particle size and shape; production of oxide MNP by gel calcination; adequate for hybrid MNPs. | Requires thermal treatment at elevated temperatures; incomplete removal of matrix components from MNP surface. | [ |
| Electrochemical | Ambient temperature environment; narrow size distribution; high purity; adequate for maghemite NPs. | Complicated and long process. | [ |
| Biosynthesis | High crystallinity; prominent T2 relaxation reduction and contrast. | Reduced control in MNP specifications; mixture of cubic, octahedral and dodecahedral MNPs; low scalability potential. | [ |
Figure 2(a) All-in-one nanoparticles of MnFe2O4siGFPCy5/PEG-RGD for theranostic purposes. (b) Schematic illustration of intracellular processes of MnFe2O4siGFPCy5/PEGRGD nanoparticles, from target-specific uptake to mRNA degradation. Reprinted with permission from [103].
Magnetic nanoparticles tuned for dual imaging and therapeutic applications.
| MNP System Description | Characteristics | Detection Methods | Therapeutic | Tumor | Reference |
|---|---|---|---|---|---|
| Gold nanorod-capped magnetite core/mesoporous silica shell nanoparticles | Mean diameter of 386.6 nm; homogenous size distribution; T2 relaxivity coefficient of 393.8 mM−1·s−1; Dox loading capacity of 30% w/w and positive therapy effect under 39–42 °C; no reported cytotoxicity <100 µg/mL; Absorption peak at 790 nm. | MRI | Doxorubicin | - | [ |
| Gold shell-core IONP | Mean diameter: 100 nm; hydrodynamic size: 179 nm; T2 relaxivity coefficient of 76.2 mM−1·s−1 | MRI; PAI | PTT | Breast | [ |
| Multicore IONP with CuS shell | Mean core diameter of 25.5 nm; hydrodynamic size: 156 nm; zeta potential: −14.1mV at pH 7; magnetization: 84 emu/g; | MRI | MHT; PTT; PDT | - | [ |
| cRGD-functionalized Doxorubicin-conjugated and 64Cu labelled SPION | Mean core diameter:10 nm; mean hydrodynamic size of the MNP: 68 nm; T2 relaxivity coefficient of 101.9 mM−1·s−1; 64Cu T1/2:12.7 h; Dox-loading capacity of 5.8% | PET; MRI | Doxorubicin | Glioblastoma | [ |
| Indium-111 labeled Trastuzumab-Doxorubicin Conjugated, and APTES-PEG coated SPION | Mean diameter: 16 nm; magnetization: 52 emu/g; radiolabel efficiency: 97.6%; trastuzumab conjugation capacity: 63.79%; | SPECT; MRI | Tumor suppression. Antibody and chemotherapeutic agents | Breast | [ |
| Manganese-doped iron oxide nanoparticles, coated with bovine serum albumin and functionalized with a cyclic Arg-Gly-Asp (cRGD) peptide and cy5 dye-labelled siRNA | Mean core diameter:15 nm. | MRI | Inhibition of Green fluorescence protein by the siRNA moiety, and interference of receptor-mediated endocytosis via targeting tumor cells overexpressed αvβ3 integrin by RGD peptide. | Breast | [ |
| Paclitaxel loaded, PEG modified liposome iron oxide MNP | Core size of 7 nm; full nanoplatform size of 168.3 nm; PDI of 0.197; zeta potential of −10.5 mV; paclitaxel entrapment efficiency above 90%. | MRI | Paclitaxel | Breast | [ |
| Liposome, ADT loaded iron oxide MNP, encapsulated with PEG | Core size of 7 nm; final size of 211 nm; PDI of 0.19; ADT loading capacity of 49.6%; T2* of 12.85 ms; | MRI | H2S | Liver | [ |
| Rituximab loaded liposome, iron oxide MNP, encapsulated with PEG | Superparamagnetic NP-PVA core size average between 7–10 nm; narrow size distribution (PDI 0.1–0.3); 44.6% SPION-PVA encapsulation efficiency; zeta potential of −9.0 mV. | MRI | Rituximab | Brain Lymphoma | [ |
Key: SPION—superparamagnetic iron oxide nanoparticle; MRI—Magnetic resonance imaging; PAI—Photoacoustic imaging; SERS—Surface Enhanced Raman Spectroscopy; APTES—aminopropyl triethoxysiliane; PEG—poly(ethylene glycol); cy5 dye—cyanine dye; cRGD—cyclic arginine-glycine-aspartate peptide; RGD—arginyl-glycyl-aspartic acid; ADT—hydrophobic anethole ditholethione; US—ultrasound; NIR—Near infrared. T2*—decay of transverse relaxation, resultant of spin-spin relaxation and inherent inhomogeneity of the main magnetic field.
List, not exhaustive, of clinical trials involving magnetic nanoparticles in cancer diagnosis and/or treatment.
| Clinical Trial | Status | MNP | Applications | Tumor | Location |
|---|---|---|---|---|---|
| MAGNABLATE I NCT02033447 | Completed | IONP for magnetic hyperthermia | Magnetic hyperthermia and MRI | Prostate cancer | University College London Hospital |
| NCT01895829 | Active | USPIO nanoparticle-ferumoxytol | MRI | Head and neck cancer | University of Texas MD Anderson Cancer Center |
| NCT00675259 | Completed | Paclitaxel albumin-stabilized nanoparticle | Chemotherapy | Breast cancer | Ohio State University Comprehensive Cancer Center Columbus, OH, USA |
| NCT00920023 | Completed | SPIO nanoparticle | MRI | Pancreatic cancer | Massachusetts General Hospital |
| NCT01927887 | Completed | USPIO nanoparticle-ferumoxytol | MRI | Thyroid cancer | Massachusetts General Hospital |
| NCT01815333 | Active | USPIO nanoparticle-ferumoxytol | MRI | Lymph node cancer | University of Texas MD Anderson Cancer Center |
Data retrieved from ClinicalTrials.gov [114] Key: SPIO—superparamagnetic iron oxide; USPIO—ultrasmall superparamagnetic iron oxide; MRI—magnetic resonance imaging.